GlassScriptPhysician profile
Edith Trevino
NPI 1346429834
$4,972.86
in general payments reported to CMS, 2019-2025
23 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $398 · 2023: $1,114 · 2024: $1,047 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,123.81 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,007.40 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $667.68 | 2021-2025 | |
| Amgen INC. | $543.62 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $533.18 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $264.61 | 2021-2024 | Bexsero, Pediarix, Trelegy Ellipta |
| Merz North America, INC. | $173.43 | 2025 | |
| Corcept Therapeutics | $124.99 | 2025 | Korlym |
| Dexcom, INC. | $86.70 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $85.50 | 2024-2025 | |
| Pfizer INC. | $72.99 | 2023-2025 | |
| Phadia US INC. | $55.44 | 2022-2024 | Immunocap |
| Gm Pharmaceuticals, INC. | $39.77 | 2025 | Vanacof |
| Allergan, INC. | $36.27 | 2021-2022 | |
| Astellas Pharma US INC | $33.18 | 2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $23.56 | 2024 | |
| Merck Sharp & Dohme LLC | $19.36 | 2022 | |
| Exact Sciences Corporation | $19.21 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.87 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $15.16 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $13.98 | 2023 | Kristalose |
| Abbott Laboratories | $13.59 | 2025 | Freestyle Libre 3 |
| Organon LLC | $2.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Trevino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.